Comparing Ozempic and Wegovy: same molecule, very different purposes

You've seen Ozempic everywhere, here's what's actually going on

Pick up any newspaper from the last two years and Ozempic is in it. Celebrities, social media, GP waiting rooms, the name is everywhere. But a lot of what circulates online conflates Ozempic with weight-loss treatment in general, and that's created genuine confusion for people trying to work out their options.

Here's the situation. Semaglutide, the active ingredient in both brands, is a GLP-1 receptor agonist: it mimics a gut hormone that slows gastric emptying, increases feelings of fullness and influences appetite signalling. Novo Nordisk developed Ozempic first, for people with type 2 diabetes, at doses up to 1 mg weekly (with a 2 mg dose also licensed for diabetes). When trials demonstrated significant weight loss as a secondary effect, the company ran a dedicated weight-management programme (the STEP trials) at higher doses. Wegovy came out of that work, licensed specifically for adults with obesity or overweight with a weight-related health condition. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose.

So when someone says "I want Ozempic for weight loss," what they usually mean is they want the effect they've read about, which is actually the Wegovy licence, at Wegovy doses, with Wegovy's clinical oversight. The two are not interchangeable on a UK prescription.

What the UK licensing actually says, and why it shapes what a prescriber can offer

The MHRA licenses medicines for specific indications. Ozempic's UK licence covers the management of type 2 diabetes in adults. Wegovy's UK licence covers weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Those are different products with different licensed populations and different dose schedules.

If you don't have type 2 diabetes, a UK prescriber has no basis to prescribe Ozempic for weight loss within normal clinical practice. And if you do have type 2 diabetes and want GLP-1 treatment, your prescriber has to weigh whether the diabetes indication (Ozempic) or the weight-management indication (Wegovy, or Mounjaro if tirzepatide is considered) is clinically appropriate for you, it's not a patient-choice decision made on a website. There's a fuller breakdown of how semaglutide's two brands relate to each other on the Wegovy and Ozempic explained page if you want to read further.

The dose difference is also clinically significant. Wegovy's escalation path runs from 0.25 mg up to a maintenance dose of 2.4 mg weekly, with the newer 7.2 mg single-dose pen approved by the MHRA on 14 April 2026 for adults with a BMI of 30 or above. Ozempic's diabetes doses top out well below that. Using a diabetes-dose product and expecting weight-loss-study results is comparing apples with something quite different.

What is actually licensed for weight loss in the UK right now

Two injectable options hold UK marketing authorisations for weight management in adults. Wegovy (semaglutide) is one. Mounjaro (tirzepatide) is the other, a dual GIP and GLP-1 receptor agonist made by Eli Lilly, and the only dual-agonist weight-loss medicine currently licensed in the UK. In head-to-head evidence from the SURMOUNT-5 trial, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. You can read a fuller side-by-side breakdown on the Wegovy vs Mounjaro comparison page.

There is also now a third option in a completely different format. Wegovy tablets (oral semaglutide) received MHRA approval on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet schedule runs from 1.5 mg daily up to a 25 mg maintenance dose and requires no refrigeration, which some people find easier to fit into daily life. The Wegovy treatment page covers all three formats.

What isn't on that list: Ozempic (type 2 diabetes only), Saxenda (liraglutide, a different GLP-1 medicine, see the Saxenda vs Wegovy comparison for context), and Rybelsus (oral semaglutide at lower doses, also diabetes only). If you're curious about how semaglutide as a molecule fits across all these brands, the semaglutide overview covers the full picture. For cost context on Wegovy specifically, the Wegovy cost page lays out what private treatment typically involves.

Getting from here to a clinically appropriate option

If you've read this far, you probably came in looking for Ozempic and have realised the route to what you actually want runs through Wegovy or Mounjaro, both prescription-only medicines that require a clinical assessment before a UK prescriber can issue a script. That assessment isn't a formality. A GPhC-registered prescriber looks at your BMI, your health history, your current medicines (including the contraception question for tirzepatide, which matters practically), and your weight-related conditions before making a decision.

One practical note: if you're planning ahead around a holiday or a busy stretch at work, orders placed with same-day dispatch before 12pm on a working day arrive the next working day via tracked DPD delivery. It's worth timing things so your first pen lands when you're at home and can start properly, not when you're away.

The weight-loss treatment overview explains how both options work and what the consultation covers. If you're ready to find out which medicine a prescriber would consider appropriate for you, start your free consultation and a GPhC-registered Independent Prescriber will review your answers the same day.